Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors

Using the Jurkat reporter T cell line for evaluating the functionality of novel chimeric antigen receptors

Background: T cells that are genetically modified with chimeric antigen receptor (CAR) hold promise for immunotherapy of cancer. Currently, there are intense efforts to improve the safety and efficacy of CAR T cell therapies against liquid and solid tumors. Earlier we designed a novel CAR backbone (...

Full description

Bibliographic Details
Main Authors: Farhana Jahan, Jan Koski, Diana Schenkwein, Seppo Ylä-Herttuala, Helka Göös, Sini Huuskonen, Markku Varjosalo, Pilvi Maliniemi, Judith Leitner, Peter Steinberger, Hans-Jörg Bühring, Kim Vettenranta, Matti Korhonen
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-02-01
Series:Frontiers in Molecular Medicine
Subjects:
FiCAR
CAR (chimeric antigen receptor) T cells
cancer
phosphoprotein
cell signaling
Online Access:https://www.frontiersin.org/articles/10.3389/fmmed.2023.1070384/full

Internet

https://www.frontiersin.org/articles/10.3389/fmmed.2023.1070384/full

Similar Items